Conceptually driven pharmacologic approaches to acute trauma.
Secondary prevention of posttraumatic stress disorder (PTSD) entails intervening in the aftermath of a traumatic event to forestall the development of PTSD. There has been little psychopharmacologic research in this area. This is surprising, given that PTSD is the mental disorder with the most clearly identified cause and onset. In a translational model of PTSD's pathogenesis presented herein: A traumatic event (unconditioned stimulus) overstimulates endogenous stress hormones (unconditioned response); these mediate an overconsolidation of the event's memory trace; recall of the event in response to reminders (conditioned stimulus); releases further stress hormones (conditioned response); these cause further overconsolidation; and the overconsolidated memory generates PTSD symptoms. Noradrenergic hyperactivity in the basolateral amygdala is hypothesized to mediate this cycle. Preventing pre-synaptic norepinephrine release with alpha2-adrenergic agonists or opioids, or blocking post-synaptic norepinephrine receptors with beta-adrenergic antagonists such as propranolol, reduces hormonally enhanced memories and fear conditioning. Two controlled studies of trauma victims presenting to emergency rooms suggest that posttrauma propranolol reduces subsequent PTSD, as does one naturalistic clinical study of morphine treatment of burned children. Cortisol both enhances memory consolidation and reduces memory retrieval, leading to mixed predictions. Two controlled studies of intensive care unit patients found that cortisol reduced PTSD. One study did not find benzodiazepines effective in preventing PTSD. Selective serotonin reuptake inhibitors, antiepileptics, and alpha2-adrenergic agonists have yet to be tried.
Pitman
Roger K
RK
Massachusetts General Hospital, Charlestown, MA 02129, USA. roger_pitman@hms.harvard.edu
Delahanty
Douglas L
DL
D000223:Adaptation, Psychological / Q000187:drug effects* / Q000502:physiology; D018674:Adrenergic Antagonists / Q000627:therapeutic use*; D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000328:Adult; D000679:Amygdala / Q000187:drug effects / Q000503:physiopathology; D000818:Animals; D002648:Child; D003214:Conditioning, Classical / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D006854:Hydrocortisone / Q000097:blood / Q000627:therapeutic use; D017774:Long-Term Potentiation / Q000187:drug effects / Q000502:physiology; D009294:Narcotics / Q000627:therapeutic use; D009638:Norepinephrine / Q000378:metabolism; D011433:Propranolol / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D013313:Stress Disorders, Post-Traumatic / Q000188:drug therapy* / Q000503:physiopathology
D018674:Adrenergic Antagonists; D000316:Adrenergic alpha-Agonists; D009294:Narcotics; D011433:Propranolol; D006854:Hydrocortisone; D009638:Norepinephrine